Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fate Therapeutics, Inc. (FATE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fate Therapeutics is a clinical-stage biopharmaceutical company whose common stock trades on the Nasdaq Global Market, and its Exchange Act reports offer detailed information on financial condition, clinical programs, and corporate actions related to its iPSC-derived cellular immunotherapy pipeline.
Among the key documents available are current reports on Form 8-K, where Fate Therapeutics reports material events such as quarterly financial results, corporate restructuring decisions, clinical data updates, and executive appointments. For example, recent 8-K filings describe financial results for specific quarters, a restructuring that includes a workforce reduction to streamline operations and extend cash runway, and detailed summaries of new and updated FT819 clinical data presented at scientific meetings. Other 8-K filings outline changes in board composition and the appointment of a Chief Financial Officer, including associated compensation terms and inducement equity awards.
Investors can also use SEC filings to confirm the company’s trading status, as Fate Therapeutics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market under the symbol FATE. Filings disclose the company’s principal executive office location by city and state, the par value of its common stock, and the use of inducement equity plans under Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, each new Fate Therapeutics filing is captured from EDGAR and paired with AI-powered summaries that highlight the most important points, such as clinical milestones, restructuring charges, or changes in leadership. Users can quickly scan Form 8-K items, then drill down into the full text for deeper analysis, helping them understand how regulatory disclosures relate to the company’s iPSC-derived CAR T-cell and NK-cell development strategy.